Does Nutrafol work for hair loss?
The evidence that Nutrafol helps comes from studies its maker supported financially. In two placebo-controlled trials in women who felt their hair was thinning, the number of thick hairs in a small patch of scalp rose by about 10% in six months on Nutrafol, against under 4% on placebo. In the men's trial, the planned hair count was not reported, because of unusable images at one site, the paper says, and the results rest on doctors' ratings of photographs and on questionnaires. A daily dose of Nutrafol Women or Men contains 25 mg of zinc, the adult upper limit Europe's food safety authority set for all sources combined, and 100 times the US daily value of biotin, which can interfere with some blood tests.
Two trials in women
Two placebo-controlled trials in women had financial support from Nutrafol's maker, Nutraceutical Wellness; their co-author Sophia Kogan worked for the company. The women felt their hair was thinning, which is not a diagnosis; those diagnosed with telogen effluvium were excluded. In 2018, with 26 women on Nutrafol Women and 14 on placebo, thick, or terminal, hairs in a patch of about 1 cm² rose 10.4% in six months, against 3.5% on placebo, with no significant change in diameter. In 2021, 70 women around the menopause took Nutrafol Women's Balance or placebo; in the 33 and 27 analysed, terminal hairs went from 68.1 to 75.1, against 69.2 to 69.5. A third placebo-controlled trial, in 21 women, registered by a New York research group in February 2017 after it had started and completed that November, has posted no results; we found no publication.
The men's trial
The men's trial, published in 2025, was funded by the maker; two of its five authors worked for the company and two advised it. It enrolled 112 men aged 21 to 61 with male pattern hair loss at Norwood stages II to IV, and analysed 52 on Nutrafol Men and 33 on placebo. Its registered primary outcome was terminal hair count, but the paper reports no counts; it says protocol deviations with the imaging device at one site left "many phototrichograms unusable" and affected no other data. Results rest on doctors' blinded ratings of photographs, which judged growth improved in 79% of men on Nutrafol and 51% on placebo, and on questionnaires. At the start, 40% of the placebo group were at stage IV, against 23% on Nutrafol. The trial was registered more than eight months after it began.
Who ran the studies
Every published clinical study of Nutrafol we found had financial support from Nutraceutical Wellness, in which Unilever agreed in 2022 to buy a majority stake. Glynis Ablon, a dermatologist with a research centre in Manhattan Beach, California, led both women's trials and helped run the men's trial, and has received research grants from the company. She also led a 2015 trial of Viviscal, another hair supplement, funded by its maker. The two women's trials were registered 56 and 47 days after they began. The other studies had no placebo group: a 2022 extension in which all the women took Nutrafol, and studies from 2022 to 2026 that compared people with their own starting point. One 2026 paper calls itself randomised in its title and "nonrandomized" in its limitations.
What the reviews found
A 2023 systematic review in JAMA Dermatology, which searched up to October 2021, listed Nutrafol among the products whose highest-quality studies showed a "potential benefit", and said its findings should be read in the context of each study's design. A 2026 network meta-analysis found that Nutrafol improved hair density against placebo, ranking it first of nine supplements on that measure, on the strength of the two women's trials. Its authors rated the hair-density evidence as a whole of moderate certainty, saw possible signs of publication bias or small-study effects, and counted the women's trials as trials in pattern hair loss although they enrolled self-perceived thinning. A 2026 meta-analysis of commercial supplements pooled total hair counts from the two women's trials and one other trial and found no significant difference from placebo, concluding that "more rigorous, independent research is needed".
What a daily dose contains
According to the NIH label database, four capsules of Nutrafol Women or Men contain 3,000 micrograms of biotin, 100 times the US daily value; 25 mg of zinc; 200 micrograms of selenium; 62.5 micrograms (2,500 IU) of vitamin D; and 1,500 micrograms retinol activity equivalents of vitamin A, as beta-carotene. Saw palmetto, ashwagandha, curcumin and marine collagen come in blends whose amounts are not listed. Europe's food safety authority sets adult upper limits, from all sources combined, of 25 mg for zinc, 255 micrograms for selenium and 100 micrograms for vitamin D; it found too little data to set one for biotin. Its vitamin A limit covers retinol, not beta-carotene, but it says smokers should avoid supplements containing beta-carotene. The American Academy of Dermatology advises taking biotin or zinc only when a blood test shows a deficiency.
Safety, and France
The placebo-controlled trials reported few side effects, mostly stomach upset, similar on Nutrafol and placebo. Labels advise asking a doctor first if taking medicines, especially blood thinners; the Women label rules out pregnancy and breastfeeding. A 2026 analysis of US adverse-event reports found a preliminary signal of raised liver enzymes for Nutrafol in 2023 to 2025, which its author calls a flag for further investigation, not a confirmed risk. A 2025 case report cites a 2024 conference abstract on a 26-year-old woman who developed liver injury with jaundice after taking Nutrafol; her liver tests improved once she stopped. We did not find Nutrafol in the French agriculture ministry's list of declared food supplements in October 2026. The EU-authorised health claims about hair say that biotin, selenium and zinc contribute "to the maintenance of normal hair" and copper to its pigmentation; none mentions growth.
Related questions
Sources
- A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair · Journal of Drugs in Dermatology, 2018 · PMID 29742189
- Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair (NCT03206567) · ClinicalTrials.gov, 2017
- A Randomized, Double-Blind, Placebo-Controlled Study of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal, and Postmenopausal Women With Thinning Hair · Journal of Drugs in Dermatology, 2021 · PMID 33400421
- Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair (NCT04048031) · ClinicalTrials.gov, 2019
- A Long-Term Study of the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal, and Postmenopausal Women · Journal of Drugs in Dermatology, 2022 · PMID 35816069
- Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females (NCT03052413) · ClinicalTrials.gov, 2017
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair · Journal of Cosmetic Dermatology, 2025 · PMID 39757794
- Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair (NCT05339958) · ClinicalTrials.gov, 2022
- A Prospective Six-month Single-blind Study Evaluating Changes in Hair Growth and Quality Using a Nutraceutical Supplement in Men and Women of Diverse Ethnicities · Journal of Clinical and Aesthetic Dermatology, 2022 · PMID 35309272
- A Prospective, Multi-Center Study to Evaluate the Safety and Efficacy of a Vegan Nutraceutical to Improve Hair Growth and Quality in Females Following a Plant-Based Diet · Journal of Drugs in Dermatology, 2024 · PMID 39093662
- Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair (NCT05332743) · ClinicalTrials.gov, 2022
- A 6-Month, Prospective, Multi-arm Study for the Efficacy of Standardized Nutraceuticals to Improve Hair Fiber Thickness and Strength · Dermatology and Therapy, 2026 · PMID 41171588
- A 6-Month Prospective, Open-Label, Randomized Study Showing Increased Hair Growth Rate in Women Using Multi-Targeting Hair Growth Nutraceuticals · Dermatology and Therapy, 2026 · PMID 42449043
- A 3-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Ability of an Extra-Strength Marine Protein Supplement to Promote Hair Growth and Decrease Shedding in Women with Self-Perceived Thinning Hair · Dermatology Research and Practice, 2015 · PMID 25883641
- Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review · JAMA Dermatology, 2023 · PMID 36449274
- Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis · Frontiers in Nutrition, 2026 · PMID 41561175
- Evaluating the Effectiveness of Commercial Oral Supplements for Hair Growth: A Systematic Review and Meta-Analysis · Journal of Cosmetic Dermatology, 2026 · PMID 41954038
- Nutrafol Women · NIH Dietary Supplement Label Database, 2025
- Nutrafol Men · NIH Dietary Supplement Label Database, 2025
- Overview on Tolerable Upper Intake Levels as derived by the Scientific Committee on Food (SCF) and the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) · European Food Safety Authority, 2025
- Hair loss: Diagnosis and treatment · American Academy of Dermatology, 2022
- Supratherapeutic vitamin D with a hair nutraceutical: A case report · JAAD Case Reports, 2025 · PMID 40791753
- Disproportionality analysis of dietary supplement adverse events in the FDA CAERS database, 2004-2025 · Food and Chemical Toxicology, 2026 · PMID 42323077
- Unilever acquires majority stake in hair wellness company Nutrafol · NutraIngredients, 2022
- Déclarations de compléments alimentaires · Ministère de l'Agriculture, de l'agro-alimentaire et de la souveraineté alimentaire (data.gouv.fr), 2026
- Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health · European Commission, 2012
Checked against its sources on 2026-11-01, by us, not by a doctor. A research register, not medical advice: talk to a dermatologist about your own case. See why we're not doctors.